LGC Biosearch Technologies

Petaluma, CA · Middleton, WI
Oligonucleotide
Program data pending ClinicalTrials.gov matching · Last scored 2026-03-15
63.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (4)

Quick Facts: LGC Biosearch Technologies

Signal Score
63.0/100 (as of 2026-03-15)
Quality Compliance
Assessment pending
Headquarters
Petaluma, CA · Middleton, WI
Modalities
Oligonucleotide
Active CGT Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CGT manufacturing intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesOligonucleotide
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 68.0
Parent company: LGC Group
Financial assessment: 68.0/100
Source: SEC EDGAR, press monitoring
Subsidiary of LGC Group
SEC FilingsParent: LGC Group
Parent company: LGC Group
Financial assessment: 68.0/100
Capacity 58.0
2 CGT manufacturing sites
Sites: Petaluma, CA, Middleton, WI
Source: SEC EDGAR, press monitoring, company profiles
2 CGT manufacturing sites
Recent Press4 articles
2 CGT manufacturing sites

Recent News 4 articles

general 2026-03-18
New automation example for fast, high-purity DNA from cells - Labroots
New automation example for fast, high-purity DNA from cells  Labroots
Source →
regulatory 2026-03-11
Amplicon Panels Market To 2035: Growth Fueled by Liquid Biopsy and Clinical NGS Integration - News and Statistics - IndexBox - Market Intelligence Platform
Amplicon Panels Market To 2035: Growth Fueled by Liquid Biopsy and Clinical NGS Integration - News and Statistics  IndexBox
Source →
general 2026-02-26
How controlled pore glass selection improves siRNA yield and manufacturing performance - SelectScience
How controlled pore glass selection improves siRNA yield and manufacturing performance - SelectScience webinar  Select Science
Source →
general 2026-02-24
Precision Chemistry in Peptide and Oligonucleotide Synthesis - AZoNano
Precision Chemistry in Peptide and Oligonucleotide Synthesis  AZoNano
Source →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Oligonucleotide CDMOs →